RU2007129264A - Полиморф cci-779 и его применение - Google Patents

Полиморф cci-779 и его применение Download PDF

Info

Publication number
RU2007129264A
RU2007129264A RU2007129264/04A RU2007129264A RU2007129264A RU 2007129264 A RU2007129264 A RU 2007129264A RU 2007129264/04 A RU2007129264/04 A RU 2007129264/04A RU 2007129264 A RU2007129264 A RU 2007129264A RU 2007129264 A RU2007129264 A RU 2007129264A
Authority
RU
Russia
Prior art keywords
ccl
polymorph
solid
tert
bme
Prior art date
Application number
RU2007129264/04A
Other languages
English (en)
Russian (ru)
Inventor
Сабодх С. ДЕШМАХ (US)
Сабодх С. ДЕШМАХ
Original Assignee
Вайет (Us)
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайет (Us), Вайет filed Critical Вайет (Us)
Publication of RU2007129264A publication Critical patent/RU2007129264A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2007129264/04A 2005-02-09 2006-01-25 Полиморф cci-779 и его применение RU2007129264A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09
US60/651,374 2005-02-09

Publications (1)

Publication Number Publication Date
RU2007129264A true RU2007129264A (ru) 2009-03-20

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007129264/04A RU2007129264A (ru) 2005-02-09 2006-01-25 Полиморф cci-779 и его применение

Country Status (19)

Country Link
US (1) US7442707B2 (enExample)
EP (1) EP1856130A1 (enExample)
JP (1) JP2008530090A (enExample)
KR (1) KR20070107030A (enExample)
CN (1) CN101115759A (enExample)
AR (1) AR052479A1 (enExample)
AU (1) AU2006213061A1 (enExample)
BR (1) BRPI0607932A2 (enExample)
CA (1) CA2595766A1 (enExample)
CR (1) CR9257A (enExample)
GT (1) GT200600044A (enExample)
IL (1) IL184560A0 (enExample)
MX (1) MX2007009590A (enExample)
NO (1) NO20073725L (enExample)
PE (1) PE20060996A1 (enExample)
RU (1) RU2007129264A (enExample)
TW (1) TW200638932A (enExample)
WO (1) WO2006086172A1 (enExample)
ZA (1) ZA200706628B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
PE20070748A1 (es) * 2005-12-07 2007-08-08 Wyeth Corp Proceso ajustable a escala para la preparacion de un 42-ester de rapamicina a partir de un boronato de 42-ester de rapamicina
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CA2749807C (en) * 2009-01-21 2015-09-29 Biocon Limited A method for determination of sirolimus stability and process for preparing its stable form
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6680330B2 (en) * 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) * 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Cci−779の位置選択的合成
EP1660081A1 (en) * 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
KR20070015544A (ko) * 2004-04-14 2007-02-05 와이어쓰 라파마이신 42-에스테르 유도체의 위치특이성 합성

Also Published As

Publication number Publication date
IL184560A0 (en) 2007-10-31
EP1856130A1 (en) 2007-11-21
KR20070107030A (ko) 2007-11-06
AU2006213061A1 (en) 2006-08-17
GT200600044A (es) 2006-11-09
BRPI0607932A2 (pt) 2016-11-08
ZA200706628B (en) 2010-01-27
CA2595766A1 (en) 2006-08-17
CN101115759A (zh) 2008-01-30
TW200638932A (en) 2006-11-16
WO2006086172A1 (en) 2006-08-17
JP2008530090A (ja) 2008-08-07
MX2007009590A (es) 2007-09-12
PE20060996A1 (es) 2006-11-13
AR052479A1 (es) 2007-03-21
US20060178392A1 (en) 2006-08-10
US7442707B2 (en) 2008-10-28
NO20073725L (no) 2007-09-05
CR9257A (es) 2007-11-23

Similar Documents

Publication Publication Date Title
KR100377159B1 (ko) 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
RU2007104518A (ru) Полиморф рапамицина ii и его применение
JP2005503386A5 (enExample)
WO2005095379B1 (en) Crystalline methanesulfonic acid addition salts of imatinib
JP2018520178A5 (enExample)
BR112019027457A2 (pt) esteramina e sal da mesma, processo para preparação de esteramina ou sal da mesma, uso de esteramina e sal da mesma, e, composição de cuidados pessoais.
CA2785998A1 (en) Darunavir polymorph and process for preparation thereof
JP2000507972A (ja) 逆溶媒を使用する逆転写酵素阻害剤の結晶化方法
CN102639522A (zh) 3-(4-氨基-1-氧代-1, 3-二氢-异吲哚-2-基)-哌啶-2, 6-二酮的固体形式及制备它们的方法
JP2008530090A5 (enExample)
RU2011148101A (ru) Новые кристаллы сольватов
CN111621014A (zh) 基于羟脯氨酸的聚合物及其制备方法和解聚方法
CA2788709A1 (en) Crystalline forms of l-malic acid salt of sunitinib
CZ20014458A3 (cs) Polymorfní formy krystalického (2-benzhydryl-l-azabicyklo[2,2,2]okt-3-yl)-(5-isopropyl-2-methoxybenzyl) amoniumchloridu jako antagonisté receptoru NK-1
JP2016108183A (ja) セメント混和剤
TH81761A (th) Cci-779 โพลีมอร์ฟ และ การใช้ของสารนั้น
JPH08510477A (ja) 新規なn−ベンゾイルメチル−ピペリジン類
EP4676492A2 (en) High purity nitric oxide releasing compounds and methods of preparing same
JP2007510715A (ja) アトバコンの新規な多形およびその調製のプロセス
WO2004083180A1 (en) Novel crystalline forms of levetiracetam
TW200829572A (en) Crystal modifications
WO2012038785A1 (en) Polymorphs of rosuvastatin acetonide calcium ((3r,5s,6e)-7-[4-(4- fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimn)in-5- yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) acetic acid calcium salt
KR20140006092A (ko) 에피루비신 히드로클로라이드의 결정화
BG98439A (bg) Кватернерни амониеви производни на (-) и (+) 10-(1-азобицикло /2.2.2/окт-3-ил-метил)-10н-фенотиазин,фармацевтични състави на тяхна основа и метод заполучаването им
JP2007532538A (ja) プロブコール誘導体の製造方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20091201